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I. INTRODUCTION
The FDA should develop regulations that require evaluation of and increase
transparency about potential bias in medical machine learning. Machine learning
(ML) relies on data sets, which may have hidden biases, resulting in medical
devices developed with ML algorithms having a risk of faulty results. All machine
learning has a potential bias issue when using biased data sets. Medical devices
using machine learning are no exception. Underrepresentation or bias in medical
data is a problem because “diverse participation [in clinical trials and biobanking
for medical research] is necessary to identify the most effective treatments in
different groups.”2 The FDA should address these potential bias issues by requiring
machine learning medical device manufacturers to disclose the demographics of
the data sets that trained the algorithm to the FDA. This includes disclosure of
underrepresented populations in the data or populations the data set did not include
at all. The FDA should use its authority to require manufacturers to monitor and
evaluate the safety, effectiveness, and reliability of the device after approval,
including any negative effect on sub-populations.3 The FDA should also increase
support for regulatory science efforts focused on developing methods to evaluate
ML-based medical software and eliminating algorithmic bias.
There is no simple solution to algorithmic bias. Every data set is unique and
presents possible bias. Without a way to accurately measure the amount of bias in

2

Terry C. Davis et al., A Qualitative Study Exploring Barriers and Facilitators of Enrolling
Underrepresented Populations in Clinical Trials and Biobanking, 7 FRONTIERS CELL AND DEV.
BIOLOGY 1, 1 (2019).
3
21 C.F.R § 814.82 (2012).
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an algorithm, the FDA must require manufacturers to have accurate reports
available about the data sets used to train the algorithm. The slogan “garbage in,
garbage out” applies to machine learning practices, as does the related phrase “bias
in, bias out.”4 Tracking the data is important because “completeness of metadata
provides information about the population, disease, and data types on which the
algorithm was trained or validated, which is essential to extrapolating assumptions
of generalizability of algorithm performance to other populations.”5 Increased
attention to the early stages of data collection and algorithm development may
allow manufacturers to create less-biased data sets. In addition, the FDA should
continue working with universities and industry experts to improve evaluation and
development of ML devices.

II. MEDICAL DATA SETS AND MACHINE LEARNING INTERSECT IN
DIAGNOSTIC HEALTHCARE TOOLS
Machine learning is “an automated process of discovering correlations
(sometimes alternatively referred to as relationships or patterns) between variables
in a dataset, often to make predictions or estimates of some outcome.” 6 Once an
individual or organization creates a machine learning algorithm, it can process a
huge amount of data, such as electronic health records, in an extremely short

4

SOLON BAROCAS ET AL., FAIRNESS AND MACHINE LEARNING: LIMITATIONS AND OPPORTUNITIES,
at 236 (2022) (ebook).
5
David Wen et al., Characteristics of Publicly Available Skin Cancer Image Datasets: a
Systematic Review, 4 LANCET DIGIT HEALTH e64, e65 (2022).
6
David Lehr & Paul Ohm, Playing with the Data: What Legal Scholars Should Learn About
Machine Learning, 51 U.C. DAVIS L. REV. 653, 671 (2017).
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amount of time. Some machine learning models can learn from real-world use and
improve performance.7 Other models use new data to upgrade or modify but do not
learn and change on the fly.
The healthcare industry uses machine learning medical devices for both
treatment and diagnosis.8 This paper will focus on diagnostic ML medical devices
rather than both because most ML devices approved by the FDA are diagnostic.9
Properly trained artificial intelligence (AI), which includes ML, “has the potential
to dramatically improve diagnosis. [AI’s] potential deserves emphasis, given that
diagnostic errors effect five percent of U.S. outpatients annually, accounting for
between six and 17 percent of adverse events.”10

A. SOURCES OF BIAS IN MEDICAL DATA SETS
ML medical device training data sets rely heavily on patient data and health
records. Patient data is an individual’s medical information and includes “past and
current health or illness, treatment history, lifestyle choices and genetic data.” 11 A

7

U.S. FOOD & DRUG ADMIN., Proposed Regulatory Framework for Modifications To Artificial
Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD), at 2
(2022), https://www.fda.gov/files/medical%20devices/published/US-FDA-Artificial-Intelligenceand-Machine-Learning-Discussion-Paper.pdf [hereinafter Discussion Paper].
8
David Lyell et al., How Machine Learning is Embedded to Support Clinician Decision Making:
An Analysis of FDA-Approved Medical Devices, 28 BMJ HEALTH & CARE INFORMATICS 1, 1
(2021).
9
IQVIA, FDA Publishes Approved List of AI/ML-enabled Medical Devices,
https://www.iqvia.com/locations/united-states/blogs/2021/10/fda-publishes-approved-list-of-aiml-enabled-medical-devices (Oct. 29, 2021); see also, U.S. FOOD & DRUG ADMIN., Artificial
Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices,
https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-andmachine-learning-aiml-enabled-medical-devices (Sept. 22, 2021).
10
Nicolas Terry, Of Regulating Healthcare AI and Robots, 21 YALE J.L. & TECH. 133, 146 (2019).
11
What is Patient Data and How is it Used?, GENETIC ALLIANCE UK, (May 3, 2016),
https://geneticalliance.org.uk/information/research-and-innovation/what-is-patient-data-and-howis-it-used/.
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health record is a collection of patient data that stores the information in one spot. 12
The healthcare industry’s use of existing healthcare technologies, such as electronic
health records, have left behind minority and low socioeconomical status
populations in the past and contributed to health disparities.13 Bias in medical data
often occurs because of health disparities, which are differences in health and
healthcare between groups that stem from broader inequalities. 14 These disparities
may adversely affect groups based on their racial or ethnic groups, gender, age,
disabilities, sexual orientation, or other characteristics historically linked to
discrimination or exclusion.15
U.S. data sets “may inadequately reflect all groups in society, or may underinclude women, and overrepresent persons of European ancestry, causing the
software to provide unreliable or unsafe recommendations for minorities.”16 In
addition, “machine learning algorithms used for medical image classification [may]
underperform on images collected from populations independent to those on which
the algorithms were trained.”17 Under-enrollment of minorities in clinical studies

12

Personal Health Records and Patient Portals, MAYO CLINIC, June 4, 2022),
https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/personal-health-record/art20047273.
13
Xinzhi Zhang et al., Big Data Science: Opportunities and Challenges to Address Minority
Health and Health Disparities in the 21st Century, 27 ETHNICITY & DISEASE 95, 97 (2017).
14
Nambi Ndugga & Samantha Artiga, Disparities in Health and Health Care: 5 Key Questions
and Answers, KAISER FAM. FOUND. (May 11, 2021), https://www.kff.org/racial-equity-and-healthpolicy/issue-brief/disparities-in-health-and-health-care-5-key-question-and-answers/.
15
Id.
16
Barbara J. Evans & Frank Pasquale, Product Liability Suits for FDA-Regulated AI/ML Software,
BROOKLYN LAW SCHOOL, Legal Studies Paper No. 656, (forthcoming 2022) (manuscript at 8),
https://ssrn.com/abstract=3719407.
17
David Wen et al., supra note 4, at 70.
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due to distrust, limited access to health care, and provider perceptions lead to
underrepresentation of minorities in data sets. 18

B. THE EFFECT OF BIAS IN MEDICAL DATA SETS
Algorithms trained on biased data sets can produce unjustly prejudicial results.
In decision-making, fairness is described as “the absence of any prejudice or
favoritism toward an individual or group based on their inherent or acquired
characteristics.”19 Representation in the development of “AI-driven healthcare
products is critical to help provide benefit to all people and avoid systematically
disadvantaging minority populations – or worse, actively reinforcing that
discrimination.”20 If the data sets reflect existing bias against minorities or other
vulnerable populations, the algorithm will adopt and reproduce this bias in the
results. If training data sets are “too small, inappropriate, inaccurate, or biased and
non-representative of patients the software later will analyze, then the software, by
its design, [likely] cannot provide accurate recommendations for their care.” 21 In
some situations, a small, inaccurate, or biased data set may still provide correct
recommendations. However, without a way to know if this is the case for each data
set, it is important to have representative data.

18

Jill Fisher & Corey Kalbaugh, Challenging Assumptions About Minority Participation in US
Clinical Research, 101 AM. J. PUB. HEALTH, at 2217, 2218-19 (2011).
19
Ninareh Mehrabi et al., A Survey on Bias and Fairness in Machine Learning, 54 ASS’N. FOR
COMPUTING MACH. SURV., 1, 11 (2022).
20
Karl Surmacz et al., Fairness in AI: How can we Avoid Bias and Disparities in Orthopedic
Applications of Artificial Intelligence?, 4 J. ORTHOPEDIC EXPERIENCE & INNOVATION, 1, 2 (2021),
https://journaloei.scholasticahq.com/article/25901-fairness-in-ai-how-can-we-avoid-bias-anddisparities-in-orthopedic-applications-of-artificial-intelligence.
21
Evans & Pasquale, supra note 15, at 13.
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A 2019 study found a widely used, seemingly effective algorithm, which used
health costs as a proxy for risk and reduced the number of Black patients identified
for extra care by more than half.22 Less money is spent on Black patients who have
the same level of need as their White counterparts, which led the algorithm to
incorrectly conclude the Black patients had fewer health issues.23 The study found
that Black patients generate lower costs than White patients, despite having a higher
number of chronic illnesses. There are two likely explanations for the disparity in
cost between the races. First, “poor patients face substantial barriers to accessing
healthcare, even when enrolled in insurance plans.”24 Second, race may affect costs
through discrimination, changes to doctor-patient relationships, or other factors. 25
The effect of these factors “is to lower health spending substantially for Black
patients, conditional on need.”26 Looking at the data of healthcare spending alone
does not account for these health disparities. Healthcare spending, combined with
other socioeconomic factors, resulted in the algorithm missing patients with a
greater need.
The delivery of healthcare is “known to vary by factors such as race, ethnicity,
and socio-economic status; therefore, it is possible that biases present in our health
care system may be inadvertently introduced into the algorithms.” 27

22

Ziad Obermeyer et al., Dissecting Racial Bias in an Algorithm used to Manage the Health of
Populations, 366 SCI. 447, 447 (2019).
23
Id. at 447.
24
Id. at 450.
25
Id.
26
Id.
27
U.S FOOD & DRUG ADMIN., ARTIFICIAL INTELLIGENCE/MACHINE LEARNING (AI/ML)-BASED
SOFTWARE AS A MEDICAL DEVICE (SAMD) ACTION PLAN, at 5 (2021)
https://www.fda.gov/media/145022/download [hereinafter Action Plan].
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Underrepresentation of populations in training data sets may lead to poorer realworld application of machine learning. For example, “if algorithms for reading
chest X-rays are trained with data from primarily male patients, the results are not
as accurate when applied to chest X-rays of female patients.”28 In dermatology,
ML-based software as a medical device (SaMD) trained on a data set with a
disproportionally high number of fair skinned images may have a poorer diagnosis
rate for patients with darker skin.29

III.HOW THE CURRENT FDA REGULATION OF MACHINE LEARNING
FAILS TO ADDRESS BIAS ISSUES
The FDA defines a locked algorithm as an algorithm that provides the same
result each time the same input is applied to it and does not change with use.30
Between 2012 and 2020, the FDA approved 161 of these locked devices using the
agency’s current pre-marketing approval process.31 This process requires
manufacturers to prepare and submit a premarket submission that corresponds to
the class of the medical device. 32 The FDA assigns devices to one of three classes
“based on the level of control necessary to assure the safety and effectiveness of

Uncovering and Removing Data Bias in Healthcare, HEALTHCARE INFO. & MGMT. SYS. SOC’Y.,
(Apr. 6, 2021), https://www.himss.org/resources/uncovering-and-removing-data-bias-healthcare.
29
Stephanie Chan et al., Machine Learning in Dermatology: Current Applications, Opportunities,
and Limitations, 10 DERMATOL THER (HEIDELB) 365, 380 (2020).
30
Discussion Paper, supra, note v6, at 3.
31
Casey Ross, As the FDA clears a flood of AI tools, missing data raise troubling questions on
safety and fairness, STAT NEWS (Feb. 3, 2021), https://www.statnews.com/2021/02/03/fdaclearances-artificial-intelligence-data/.
32
Overview of Device Regulation, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance/overview-device-regulation(Sept. 4,
2020).
28
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the device.”33 The manufacturer, not the software, controls all algorithm updates
when it is locked. Once the medical device is approved, the FDA expects the
manufacturer to comply with applicable regulatory controls, including
establishment registration and device listing. This process has worked for previous
locked medical devices because “in a locked algorithm, the same input will always
produce the same result unless the developer updates the program.” 34
In contrast, a machine learning medical device with an unlocked algorithm,
which can modify its behavior with changes in the environment or information, will
not always have the same input. In a 2019 paper titled Developing A Software
Precertification Program: a Working Model, the FDA stated that the agency’s
“traditional approach for the regulation of hardware-based medical devices is not
well-suited for the faster, iterative design and development, and type of validation
used for software device functions, including SaMD.”35

A. RELEASE OF AI/ML ACTION PLAN
The FDA released a 2021 AI/ML Action Plan that outlined the agency’s
intended steps regarding regulation of machine learning medical devices.36 The
Action Plan included details of what the FDA called a Predetermined Change
Control Plan. The Predetermined Change Control Plan included an SaMD Pre-

33

Classify Your Medical Device, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/medicaldevices/overview-device-regulation/classify-your-medical-device (Feb. 7, 2020).
34
How FDA Regulates Artificial Intelligence in Medical Products, THE PEW CHARITABLE TRUSTS,
(Aug. 5, 2021), https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2021/08/how-fdaregulates-artificial-intelligence-in-medical-products.
35
U.S. FOOD & DRUG ADMIN., DEVELOPING A SOFTWARE PRE-CERTIFICATION PROGRAM: A
WORKING MODEL, at 6 (2019) https://www.fda.gov/media/119722/download.
36
Action Plan, supra note 26, 1-7.
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Specifications section and an Algorithm Change Protocol. Under SaMD PreSpecifications, the FDA would require manufacturers to describe what aspects the
medical device manufacturer intended to change through algorithmic learning. The
Algorithm Change Protocol would require an ML medical device manufacturer to
explain the intended changes and adaptations of the algorithm to the FDA. The
FDA would essentially review the planned future changes before the changes went
into effect.

B. FDA RELIANCE ON MANUFACTURERS FOR DEVELOPMENT
AND EVALUATION
The FDA will rely on ML medical device manufacturers following Good
Machine Learning Practices (GMLP) in the development and evaluation of the
manufacturers’ medical devices.37 Along with Health Canada and the United
Kingdom’s Medicines and Healthcare products Regulatory Agency, the FDA
identified ten guiding principles to “inform development of GMLP.” 38 The FDA
continues to develop these standards but intends for the standards to guide
“responsible innovations in [the AI/ML] area.” 39 Public feedback about the
Proposed Regulatory Framework, a discussion paper released by the FDA detailing
the agency’s potential future regulation of AI/ML devices, stated the need for
manufacturers to “clearly describe the data used to train the algorithm…the role

37

U.S Food & Drug Admin., Good Machine Learning Practice for Medical Device Development:
Guiding Principles, https://www.fda.gov/medical-devices/software-medical-device-samd/goodmachine-learning-practice-medical-device-development-guiding-principles (Oct. 27, 2021).
38
Id.
39
Id.
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intended to be served by its output, and the evidence of the device’s performance.” 40
In response, the FDA said it intended to consider the public input in order to
determine what types of information the agency would recommend manufacturers
disclose to users.41
Although this is a step in the right direction, the FDA needs to do more than
recommend information for manufacturers to provide. The FDA should require
manufacturers to report to the FDA the data used to train the algorithm, the intended
role of the output, and evidence of the device’s performance. The FDA identified
the importance of real-world performance monitoring.42 This data would allow the
FDA to “understand how their products are being used, identify opportunities for
improvements, and respond proactively to safety or usability concerns.”43

IV.

IMPROVING PRE AND POST MARKET REQUIREMENTS FOR
MANUFACTURERS CREATING MACHINE LEARNING DEVICES

The Federal Food, Drug, & Cosmetics Act (FD&C Act) allows the FDA to
regulate medical devices. The FDA must make decisions about requirements for
manufacturers that are broad enough to encompass the many types of devices
created while promoting safe and effective development. Using the agency’s
current regulatory tools as a starting framework, the FDA must implement changes
that focus on the health disparities and potential bias during pre-market approval
and require higher review during post market to properly monitor the devices.

40

Action Plan, supra note 26, at 5.
Id.
42
Id. at 6.
43
Id.
41
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A. REQUIRED LABELING
MEDICAL DEVICES

OF

MACHINE

LEARNING

To increase transparency and communicate risk to consumers of ML
medical devices, the FDA should require ML medical devices to include a label
describing the data used to train the algorithm. Manufacturers may place the label
on the device itself or include the label or other written, printed, or graphic matter
upon any containers or wrappers, or accompanying the device while the device is
held for sale after shipment or delivery for shipment in interstate commerce. 44 If
manufacturers fail to do so, the FDA could find the manufacturer in violation of
§502 of the FD&C Act and halt or withdraw marketing approval of the device. §502
states a device is misbranded if the device’s labeling “is false or misleading.”45
Under §502(a), the FDA can find a label in violation of the law if it considers the
label deceptive.
“It is not a necessary condition that the labeling [is] flatly and badly false;
the word ‘misleading’ in the [FD&C Act] means that the labeling is deceptive if it
[creates] or leads to a false impression in the mind of the reader. A ‘false
impression’ may result not only from a false or deceptive statement, but may also
be instilled in the mind of the purchaser by ambiguity or misdirection. It may also
be caused by failure to inform the consumer of facts that are relevant to those
statements actually made. In other words, the label that remains silent as to certain
consequences may be as deceptive as the label that contains extravagant clauses.” 46

44

U.S Food & Drug Admin., Device Labeling, https://www.fda.gov/medical-devices/overviewdevice-regulation/device-labeling (Oct. 23, 2020).
45
Federal Food, Drug, and Cosmetic Act (FD&C) § 502, 21 U.S.C 352(a) (2010).
46
Id.
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The FDA may issue warning letters or seize FDA-regulated products that
are adulterated or misbranded within the meaning of the FD&C Act. A seizure
removes the products in violation from commerce. Of the 161 locked AI products
approved by the FDA between 2012 and 2020, “only 73 disclosed the amount of
patient data used to validate the performance of their device in public
devices,…only seven reported the racial makeup of their study population, and just
13 provided a gender breakdown.” 47 It is important that physicians and medical
professionals using these devices in practice understand the limitations and possible
adverse outcomes on certain populations. For example, an algorithm developed in
a large academic medical center but used by a small, rural hospital “may
recommend treatments that are not available or appropriate in a facility with less
access to specialists and cutting-edge technology.”48

B. REPORTING AND PERFORMANCE REQUIRMENTS
The FDA must implement reporting and performance requirements for
manufacturers of ML medical devices. Because the FDA plans to rely on
manufacturers to describe how the algorithms in the manufacturers’ devices will
change and adapt, the agency must deny and withdraw approval of medical devices
at any stage of the process if necessary. The current approval process for fixed
devices requires manufacturers to stay in compliance with regulatory controls. The
FDA should have the same requirements for manufacturers of unlocked algorithms.

47
48

Casey Ross, supra note 30.
The Pew Charitable Trusts, supra note 33.

432

The FDA must require ML medical device manufacturers to provide the
agency with clinical data prior to approval. Under the current pre-market
requirements, developers of Class III devices, which are devices the FDA considers
high risk, must submit clinical evidence that the product’s benefits outweigh the
risks.49 This application, called a Premarket Approval (PMA), must meet data
requirements to show the safety and effectiveness of the device. Clinical
investigations include “study protocols, safety and effectiveness data, adverse
reactions and complications, device failure and replacements, patient information,
patient complaints, tabulations of data from all individual subjects, and results of
statistical evidence.”50 The FDA requires devices seeking PMA to meet post
approval requirements, including “continuing evaluation and periodic reporting on
the safety, effectiveness, and reliability of the device for its intended use. When
reporting is required, the FDA will state in the PMA approval order the reason or
purpose for such requirement, the number of patients to evaluate, and the required
reports to submit.51 The agency should adopt a similar standard for all ML medical
devices, regardless of the risk category.
Currently, manufacturers may choose to conduct studies for clinical
validation after their devices are approved by the FDA. This is often done by
working with providers in certain hospitals to test the products. 52 The FDA should

49

Id.
U.S Food & Drug Admin., Premarket Approval, https://www.fda.gov/medicaldevices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approvalpma (May 16, 2019).
51
21 C.F.R. § 814.82 (2012).
52
Casey Ross, Illuminating the black box: Five ways the FDA could build transparency into AI
devices, STAT NEWS (Oct. 18, 2021), https://www.statnews.com/2021/10/18/fda-artificialintelligence-data-transparency/.
50
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require manufacturers of machine learning medical devices to conduct a clinical
study to review the device’s performance following the agency’s approval. 53
§519(a)(1)(B) of the FD&C Act requires a device manufacturer to report to the
Secretary if it becomes aware of information suggesting that one of the
manufacturer’s devices has malfunctioned, and that “such device... would be likely
to cause or contribute to a death or serious injury if the malfunction were to recur.” 54
§519 also requires that “every person who is a manufacturer or importer of a device
intended for human use shall establish and maintain such records, make such
reports, and provide such information, as the Secretary may by regulation
reasonably require to assure that such device is not adulterated or misbranded and
to otherwise assure its safety and effectiveness.” 55
The FDA’s Good Machine Learning Practices guidance document aligns with
the statutory language of §519 requiring records and reports. Post-market real world
performance reporting is encompassed by the requirement of §519(a)(1)(B) to
report to the Secretary any information of device malfunctions. For ML medical
devices, device malfunctions should include errors in expected behaviors and
disparate results for certain populations in real-world use. Under §519, the
Secretary could then use the report to assess the safety and effectiveness of the
device in real-world use.

53

Jeremy Jordan, Effective testing for machine learning systems, JEREMY JORDAN (Aug. 19,
2020), https://www.jeremyjordan.me/testing-ml/.
54 Federal Food, Drug, and Cosmetic Act (FD&C) § 502, 21 U.S.C. § 519(a)(1)(B) (2010).
55
Id.
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V. CONCLUSION
The FDA should create functional regulations for the growing number of
machine learning medical devices. The healthcare system is increasingly using
these devices for diagnosis. Machine learning devices trained on biased data sets
are susceptible to furthering certain types of bias and generating flawed outcomes.
The FDA should require ML medical devices to include a label that describes the
demographics of the tested population. If manufacturers fail to include this
information, the FDA could determine the label false or misleading under §502 of
the FD&C Act and stop sales of the device. After approval, the FDA should use
§814.89(2) and §519 to require manufacturers to report and evaluate the real-world
performance of their approved devices. These reviews should include studies for
clinical validation or model evaluation and model testing. While addressing bias in
diagnostic medical machine learning devices will take more than the FDA, the
agency should continue to support efforts to find an effective way to mitigate and
measure bias.
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